JP2555389B2 - Hair restorer - Google Patents
Hair restorerInfo
- Publication number
- JP2555389B2 JP2555389B2 JP32357087A JP32357087A JP2555389B2 JP 2555389 B2 JP2555389 B2 JP 2555389B2 JP 32357087 A JP32357087 A JP 32357087A JP 32357087 A JP32357087 A JP 32357087A JP 2555389 B2 JP2555389 B2 JP 2555389B2
- Authority
- JP
- Japan
- Prior art keywords
- sialic acid
- hair
- acid
- nourishing agent
- hair nourishing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は、新規な養毛料に関するものである。TECHNICAL FIELD The present invention relates to a novel hair nourishing agent.
従来、禿や脱毛の原因としては、毛根、皮脂腺等の器
官における弾性ホルモンの活性化、毛包への血流量の低
下、皮脂の分泌過剰、酸化物等の生成、細菌の繁殖等に
よる頭皮の異常、遺伝的要素、ストレス等による神経
症、疾病による二次的なものおよび老化等が考えられ
る。Conventionally, the causes of baldness and hair loss are activation of elastic hormones in organs such as hair roots and sebaceous glands, decrease in blood flow to hair follicles, excessive secretion of sebum, production of oxides, etc. Abnormalities, genetic factors, neurosis due to stress, etc., secondary ones due to diseases, and aging are considered.
このため、従来の養毛剤には、前記の原因を取り除い
たり、又は軽減する作用をもつ化合物が一般に配合され
ている。例えば、ビタミンB等のビタミン類、メチオニ
ン等のアミノ酸類、アセチルコリン誘導体等の血管拡張
剤、紫根エキス等の抗炎症剤、エストラジオールなどの
女性ホルモン剤、セファランチンなどの皮膚機能亢進剤
などが配合され、脱毛症の予防及び治療に用いられてい
る。Therefore, a conventional hair nourishing agent is generally blended with a compound having an action of removing or reducing the above-mentioned causes. For example, vitamins such as vitamin B, amino acids such as methionine, vasodilators such as acetylcholine derivatives, anti-inflammatory agents such as purple root extract, female hormone agents such as estradiol, and skin function-enhancing agents such as cepharanthin are blended, It is used for the prevention and treatment of alopecia.
しかしながら、脱毛や発毛の機構は非常に複雑であ
り、単に男性ホルモンの活性化を阻害したり、毛包の血
流量を増加させるだけでは禿や脱毛を充分に防止するこ
とはできない。従来の養毛剤は一部の人に対してのみ、
フケ、カユミ、抜毛の予防又は改善効果が認められてい
るが、今だ満足すべき発毛、育毛促進又は脱毛防止効果
を発揮するものは得られていない。However, the mechanism of hair loss and hair growth is very complicated, and baldness and hair loss cannot be sufficiently prevented by merely inhibiting the activation of male hormones or increasing the blood flow rate of the hair follicle. Conventional hair nourishing agents only for some people,
Although the effect of preventing or improving dandruff, itchiness, and hair loss has been recognized, no one has yet achieved a satisfactory effect on hair growth, hair growth promotion or hair loss prevention.
本発明者等は、上記の事情に鑑み、脱毛に対して有効
であり、優れた養毛効果を持つ物質を得るべく鋭意研究
を重ねた結果、シアル酸並びにシアル酸誘導体に優れた
養毛効果を有することを見出し、本発明を完成するに至
った。In view of the above circumstances, the present inventors have conducted extensive studies to obtain a substance that is effective for hair loss and has an excellent hair-growth effect, and as a result, has an excellent hair-growth effect for sialic acid and sialic acid derivatives. The present invention has been completed and the present invention has been completed.
即ち、本発明はシアル酸及びシアル酸誘導体より成る
群から選択された一種又は二種以上を含有してなる養毛
剤を提供するものである。That is, the present invention provides a hair nourishing agent containing one or more selected from the group consisting of sialic acid and sialic acid derivatives.
以下、本発明の構成について詳述する。 Hereinafter, the configuration of the present invention will be described in detail.
本発明に用いられるシアル酸は公知の物質であり、ポ
リヒドロキシモノアミノカルボン酸(ノイラミン酸)の
N−アシル及びN−アシル、O−アシル誘導体の総称
で、シアリン酸とも言われる。The sialic acid used in the present invention is a known substance, and is a generic term for N-acyl and N-acyl, O-acyl derivatives of polyhydroxymonoaminocarboxylic acid (neuraminic acid), and is also called sialic acid.
シアル酸は各種の生物に含まれ、通常細胞表層糖質を
構成して糖タン白質や糖脂質の末端にグリコシド結合し
て存在する。特に脳、神経、血液、顎下腺、ムチン質、
初乳に多くは存在するが、遊離して血清や体液、尿中に
も存在する。生物界にいちばん多く見出される代表的な
シアル酸はN−アセチルノイラミン酸(NANA:分子量 3
09)で、融点185〜187℃、▲[α]20 D▼−32°±2°
の白色粉体である。Sialic acid is contained in various organisms and normally constitutes cell surface saccharides and is present by glycosidic bonds to the ends of sugar proteins and glycolipids. Especially the brain, nerves, blood, submandibular gland, mucinous,
Most are present in colostrum, but are also liberated and present in serum, body fluids, and urine. The most representative sialic acid found in the living world is N-acetylneuraminic acid (NANA: molecular weight 3
09), melting point 185-187 ℃, ▲ [α] 20 D ▼ −32 ° ± 2 °
It is a white powder of.
シアル酸並びにシアル酸誘導体の生物学的薬理作用は
細胞表面の陰性荷電への寄与、細胞の特異的認識機構へ
の関与、ウィルスによる赤血球凝集反応や血液タンパク
質のホーミング現象等に関することが知られている。最
近では、シアル酸について去痰活性(特開昭61−6841
8)、抗炎症効果(特開昭62−145015)並びにシアル酸
結合オリゴ糖の栄養効果(特開昭61−152233)等の報告
がなされている。The biological pharmacological actions of sialic acid and sialic acid derivatives are known to contribute to the negative charge on the cell surface, participate in the specific recognition mechanism of cells, hemagglutination reaction by viruses, homing phenomenon of blood proteins, etc. There is. Recently, expectorant activity on sialic acid has been disclosed (Japanese Patent Application Laid-Open No. 61-6841).
8), anti-inflammatory effect (JP-A-62-145015) and nutritional effect of sialic acid-linked oligosaccharide (JP-A-61-152233).
しかしながら、養毛効果をもつことは、いまだ知られ
ていない。本発明書において「養毛効果」又は「養毛作
用」とは脱毛予防、毛生及び発毛の促進並びに育毛を意
味する。However, it has not yet been known to have a hair-feeding effect. In the present specification, the "hair nourishing effect" or "hair nourishing action" means hair loss prevention, promotion of hair growth and hair growth, and hair growth.
シアル酸並びにシアル酸誘導体の製造方法は合成法、
天然抽出法(原料:卵白、顎下腺ムチン、胎盤エキス、
大腸菌から得られるコロミン酸等)等が挙げられるが、
安価な点から乳原料抽出法(特許第1191212、特許第125
2988、特開昭59−184197等)が特に好ましい。A method for producing sialic acid and a sialic acid derivative is a synthetic method,
Natural extraction method (raw material: egg white, submandibular gland mucin, placenta extract,
Colominic acid and the like obtained from E. coli)
The milk raw material extraction method (Patent No. 1191212, Patent No. 125)
2988, JP-A-59-184197, etc.) are particularly preferable.
以下に本発明に係る化合物の乳抽出法による製造例を
示す。乳抽出法で用いる乳は、生乳、羊乳、母乳その他
自由に選択でき、更に精製の度合により、シアル酸含有
濃度を調節できるので、用途、用法、剤型、目的に合わ
せて製造法を選択できるものである。尚、本発明はこれ
により限定されるものではない。The production examples of the compound according to the present invention by the milk extraction method are shown below. Milk used in the milk extraction method can be freely selected from raw milk, sheep milk, breast milk, and the like, and the concentration of sialic acid can be adjusted depending on the degree of purification.Therefore, the production method is selected according to the application, usage, dosage form, and purpose. It is possible. The present invention is not limited to this.
(製造例I)シアル酸 チーズホエー10tに塩酸28kgを添加してpHを2に調節
した後、92℃で60分間過熱して加水分解を行った。得ら
れたホエーの加水分解をスクリューデカンターを用いて
加熱により凝固したタンパク質を除去してシアル酸含有
液を得た。次いで、シアル酸含有液を電解透析装置の脱
塩糖に入れて伝道度2mS/cmまで脱塩した後、一旦透析を
中止して濃縮糖液を廃棄した。次いで濃縮槽に蒸留水30
lを入れて再び伝導度50μS/cmまで透析を行った。透析
終了後、濃縮糖液を濃縮・乾燥して白色粉末600gを得
た。このように得られた粉末の遊離シアル酸純度は約97
%であった。(Production Example I) Sialic acid 10 kg of cheese whey was added with 28 kg of hydrochloric acid to adjust the pH to 2, and then heated at 92 ° C for 60 minutes for hydrolysis. The obtained whey was hydrolyzed by heating with a screw decanter to remove proteins coagulated by heating to obtain a sialic acid-containing liquid. Then, the sialic acid-containing solution was put into desalted sugar of the electrolytic dialysis apparatus to desalt the conductivity to 2 mS / cm, and then the dialysis was stopped once and the concentrated sugar solution was discarded. Then add 30 distilled water to the concentration tank.
Then, dialysis was carried out again by adding l to a conductivity of 50 μS / cm. After the dialysis, the concentrated sugar solution was concentrated and dried to obtain 600 g of white powder. The powder thus obtained has a free sialic acid purity of about 97.
%Met.
(実施例2)シアル酸塩 前述の遊離シアル酸を苛性ソーダで調整し、シアル酸
Naを得る。この他、Mg、K、リン酸、アミノ酸塩等自由
に目的に応じて塩を選択し製造できる。(Example 2) Sialic acid salt The above-mentioned free sialic acid was adjusted with caustic soda to prepare sialic acid.
Get Na. In addition, salts such as Mg, K, phosphoric acid, and amino acid salts can be freely selected and produced according to the purpose.
(製造例3)シアル酸結合オリゴ糖 牛乳或いはチーズホエーを限外濾過して調整した濾液
を、全固形20%まで減圧濃縮した。この液25Kgを電気伝
導度が20μS/cmになるまで電気透析した後、ダウエック
ス1×2(2kg)を充填したカラムに通じてオリゴ糖を
吸着させた。次いで、このカラムに20kgの水を通して、
中性糖を除去した後、0.5M塩酸を通じてカラムに吸着し
たオリゴ糖を溶出させた。得られた溶出液のpHを30%苛
性ソーダでpH7.0に調整後、再び電気伝導度が150μS/cm
になるまで電気透析した。得られた透析液を濃縮・乾燥
して白色粉末100gを得た。このようにして得た粉末のシ
アル酸結合オリゴ糖純度は90%であった。(Production Example 3) Sialic acid-bound oligosaccharide The filtrate prepared by ultrafiltration of milk or cheese whey was concentrated under reduced pressure to a total solid content of 20%. This solution (25 kg) was electrodialyzed to an electric conductivity of 20 μS / cm, and then passed through a column packed with Dowex 1 × 2 (2 kg) to adsorb oligosaccharides. Then, 20 kg of water was passed through the column,
After removing the neutral sugar, the oligosaccharide adsorbed on the column was eluted with 0.5 M hydrochloric acid. After adjusting the pH of the obtained eluate to pH 7.0 with 30% caustic soda, the electrical conductivity was again 150 μS / cm.
Electrodialysis was performed until. The obtained dialysate was concentrated and dried to obtain 100 g of white powder. The powder thus obtained had a sialic acid-linked oligosaccharide purity of 90%.
(製造例4)シアル酸結合タン白質 レンネットガゼインカード廃液300lをフォードラタン
クで75℃、30分間加熱殺菌した後に、40℃まで冷却し、
濃塩酸でpHを4.6に調整した。約30分間静置し、沈澱を
生成させた液をクラリファイヤーに通しpHを7.0に戻し
た後、清澄液をRO膜で濃縮、脱塩した。10倍まで濃縮し
た後、濃縮液に水を加えて再び10倍まで濃縮した。得ら
れた濃縮液を乾燥して白色粉末1.3kgを得た。このよう
にして得た粉末のシアル酸結合タン白質の純度は約80%
あった。(Production Example 4) 300 L of sialic acid-bonded protein rennet gazein curd waste liquid was sterilized by heating in a Fordora tank at 75 ° C for 30 minutes, and then cooled to 40 ° C.
The pH was adjusted to 4.6 with concentrated hydrochloric acid. The mixture was allowed to stand for about 30 minutes, the liquid in which a precipitate was generated was passed through a clarifier to return the pH to 7.0, and then the clear liquid was concentrated and desalted with an RO membrane. After concentrating up to 10 times, water was added to the concentrated solution to concentrate up to 10 times again. The obtained concentrated liquid was dried to obtain 1.3 kg of white powder. The sialic acid-binding protein of the powder thus obtained has a purity of about 80%.
there were.
(製造例5)シアル酸結合脂質 バターミルク粉15kgにクロロホルム−メタノール混液
(1:1)を100l加え室温で30分間攪拌し抽出した。次に
クロロホルム−メタノール混液を回収しイオン交換樹脂
(DEAE−Toyopearlアセテート型)1に通じてシアル
酸結合脂質を吸着させ、次いでクロロホルム−メタノー
ル混液(1:1)2lで樹脂を洗浄した後、0.5M酢酸ナトリ
ウム−メタノール溶液4lでシアル酸結合脂質を溶出し
た。溶出液を濃縮しメタノールを除去した後、水5lを加
えて限外濾過で脱塩とシアル酸結合脂質の濃縮を行っ
た。シアル酸結合脂質を含む濃縮液をエバポレータで乾
固した後、シリカゲルカラム(4.0×50cm)に通じシア
ル酸結合脂質を吸着させ、次いでクロロホルム1、ク
ロロホルムーメタノール混液(4:1)1で順次洗浄し
た後、クロロホルム−メタノール混液(2:8)の混液で
シアル酸結合脂質を溶出した。溶出液をエバポレータで
蒸発乾固し白色粉末15gを得た。(Production Example 5) Sialic acid-bonded lipid 15 kg of buttermilk powder was mixed with 100 l of a chloroform-methanol mixture (1: 1) and stirred at room temperature for 30 minutes for extraction. Next, the chloroform-methanol mixed solution was collected and passed through an ion exchange resin (DEAE-Toyopearl acetate type) 1 to adsorb the sialic acid-bound lipid, and then the resin was washed with 2 l of a chloroform-methanol mixed solution (1: 1), and then 0.5 The sialic acid-bound lipid was eluted with 4 L of M sodium acetate-methanol solution. The eluate was concentrated to remove methanol, 5 l of water was added, and desalting and concentration of sialic acid-bound lipid were performed by ultrafiltration. After the concentrated solution containing sialic acid-bound lipid was dried with an evaporator, it was passed through a silica gel column (4.0 x 50 cm) to adsorb the sialic acid-bound lipid, and then washed sequentially with chloroform 1 and chloroform-methanol mixture (4: 1) 1. After that, the sialic acid-bound lipid was eluted with a mixed solution of chloroform-methanol mixed solution (2: 8). The eluate was evaporated to dryness with an evaporator to obtain 15 g of a white powder.
このようにして得られた粉末のシアル酸結合脂質の純
度は薄層クロマトグラフィーで90%以上(レゾルシノー
ル法)であった。The purity of the sialic acid-bound lipid in the powder thus obtained was 90% or more by thin layer chromatography (resorcinol method).
次にシアル酸及びシアル酸誘導体の安全性試験を実施
したので、その結果を示す。Next, the safety test of sialic acid and sialic acid derivatives was carried out, and the results are shown.
急性毒性試験 製造例1〜5で製造したシアル酸、シアル酸Na、シア
ル酸結合オリゴ糖、シアル酸結合タン白、シアル酸結合
脂質各々を被験物質として、ICR系雌性マウス(6週
齢、1群5匹)を用い、腹腔内投与は0.5%カルボキシ
メチルセルロースナトリウム/生理食塩液に各被験物質
2重量%となるように懸濁させたものを22 1/2Gの注射
針を使用して、又、経口投与はオリーブ油に各被験物質
5重量%となるように懸濁させたものを経口針を使用し
て、腹腔内投与は60ml/kg、経口投与は30ml/kgを与え
た。その結果、全部の被験物質について7日間の観察期
間中に死亡例、体重の減少及び特記すべき中毒症状は認
められず、また7日間に行った部検においても何等異常
は認められなかった。Acute toxicity test Using sialic acid, Na sialic acid, sialic acid-binding oligosaccharide, sialic acid-binding protein, and sialic acid-binding lipid produced in Production Examples 1 to 5 as test substances, ICR female mice (6 weeks old, 1 (Group of 5 animals) was intraperitoneally administered by suspending 0.5% sodium carboxymethylcellulose / physiological saline solution to a concentration of 2% by weight of each test substance using a 22 1 / 2G injection needle. Oral administration was carried out by suspending 5% by weight of each test substance in olive oil using an oral needle, and intraperitoneally administered at 60 ml / kg and orally administered at 30 ml / kg. As a result, no deaths, weight loss, or notable toxic symptoms were not observed during the 7-day observation period for all test substances, and no abnormalities were observed in the biopsy performed for 7 days.
この結果から明らかなようにシアル酸及びシアル酸誘
導体の急性毒性値(LD50)は、腹腔内投与で1200mg/kg
以上、経口投与で1500mg/kg以上であり、安全性が高い
ことが判明した。As is clear from these results, the acute toxicity value (LD 50 ) of sialic acid and sialic acid derivatives is 1200 mg / kg after intraperitoneal administration.
As mentioned above, it was proved to be highly safe with oral administration of 1500 mg / kg or more.
次にシアル酸及びシアル酸誘導体を養毛剤として適用
するための製剤化について述べる。Next, formulation for applying sialic acid and a sialic acid derivative as a hair nourishing agent will be described.
本発明の養毛剤は、シアル酸、シアル酸誘導体の他
に、製薬上、許容することのできる添加剤及びその他の
薬剤を加えた混合物の形で使用できる。但し、シアル酸
は酸、アルカリ、光に対しての安定性に問題があり、長
期保存に適さないため安定性の良いシアル酸誘導体を用
いた方が好ましい。The hair nourishing agent of the present invention can be used in the form of a mixture containing pharmaceutically acceptable additives and other agents in addition to sialic acid and sialic acid derivatives. However, since sialic acid has a problem with stability to acid, alkali and light and is not suitable for long-term storage, it is preferable to use a sialic acid derivative having good stability.
前記の添加剤としては、例えば、塩化カルプロニウ
ム、ミノキシジル、ジアゾキサイド等の血管拡張剤、エ
ストラジオール等の女性ホルモン剤、メチオニン等のア
ミノ酸類、ビタミンB群等のビタモン類、冬虫夏草等の
生薬類、ペンタデカン酸、及びこれらのトリグリセリド
類等の皮膚機能亢進剤、オキセンドロン等の抵男性ホル
モン剤、ヒノキチオール、ヘキサクロロフェン、フェノ
ール、ZPT、トコフェリルレチノエート、ビタミンE・
ニコチン酸エステル、ビタミンE・酢酸エステル、硫化
セレン、チオキソロン、イオウ、レゾルシン、テトラク
ロロサリチルアニリド、オクタデシルトリメチルアンモ
ニウムクロリド、ヘキサデシルジメチルベンジルアンモ
ニウムクロリド等の第4級アンモニウム塩、塩化ベンザ
ルコニウム、セチルピリジニウムクロリド、ウンデシレ
ン酸、トリクロロカルバニリド及びビチオノール等の抗
フケ剤、グリチルリチン酸及びそのアンモニウム塩等の
誘導体、アラントイン、メントール等の消炎或は清涼
剤、サチチル酸、亜鉛及びその化合物、乳酸及びそのア
ルキルエステル、ビタミン類、生薬成分等の薬剤、オリ
ーブ油、マカデミアナッツ油、スクワラン等の動植物
油、流動パラフィンに代表される炭化水素油、イソプロ
ピルミリステート、セチルイソオクタノエート、2−エ
チルヘキシルパルミテート等のエステル油、ミツロウ等
のワックス類、高級脂肪酸、高級アルコール等の油分、
水、乳酸及びそのエチルエステル等の誘導体、ポリエチ
レングリコール、ソルビトール等の多価アルコール、エ
タノール等の低級アルコール、ムコ多糖類(コンドロイ
チン硫酸、ヒアルロン酸及びそれらの塩等)、ピロリド
ンカルボン酸塩、プロテオグリカン、コラーゲン、グリ
セリン等の保湿剤、界面活性剤、香料、酸化防止剤、紫
外線吸収剤、色素等を挙げることができ、これらを一種
又は二種以上混合して使用する。Examples of the additives include vasodilators such as carpronium chloride, minoxidil and diazoxide, female hormone agents such as estradiol, amino acids such as methionine, vitamins such as B vitamins, herbs such as Cordyceps sinensis, pentadecanoic acid. , And skin function enhancers such as triglycerides, male androgen agents such as oxendron, hinokitiol, hexachlorophene, phenol, ZPT, tocopheryl retinoate, vitamin E
Quaternary ammonium salts such as nicotinic acid ester, vitamin E / acetic acid ester, selenium sulfide, thioxolone, sulfur, resorcinol, tetrachlorosalicylanilide, octadecyltrimethylammonium chloride, hexadecyldimethylbenzylammonium chloride, benzalkonium chloride, cetylpyridinium Antidandruff agents such as chloride, undecylenic acid, trichlorocarbanilide and bithionol, derivatives of glycyrrhizinic acid and its ammonium salt, anti-inflammatory or cooling agents such as allantoin and menthol, salicylic acid, zinc and its compounds, lactic acid and its alkyl Drugs such as esters, vitamins, herbal medicines, olive oil, macadamia nut oil, animal and vegetable oils such as squalane, hydrocarbon oils represented by liquid paraffin, isopropyl myristate, se Louis Seo octanoate, ester oils such as 2-ethylhexyl palmitate, waxes such as beeswax, higher fatty acids, higher alcohols such as oil,
Water, derivatives such as lactic acid and its ethyl ester, polyhydric alcohols such as polyethylene glycol and sorbitol, lower alcohols such as ethanol, mucopolysaccharides (chondroitin sulfate, hyaluronic acid and salts thereof, etc.), pyrrolidone carboxylate, proteoglycan, Examples thereof include humectants such as collagen and glycerin, surfactants, fragrances, antioxidants, ultraviolet absorbers, pigments, and the like, and these are used alone or in combination of two or more.
本発明の養毛剤の剤型は、薬効を得るに適したもので
あれば任意の形態が使用でき、例えば、粉末、顆粒、散
剤、錠剤、カプセル剤、シロップ剤、座剤、注射剤、軟
膏剤等である。この中で外用剤が使用簡便な点から好ま
しく、外用できるものであれば任意の形態でよく、例え
ば、ローション、リニメント、乳液等の外用液剤、クリ
ーム、軟膏、パスタ、パップ、ゼリー、スプレー等の外
用半固型剤等を挙げることができる。As the dosage form of the hair nourishing agent of the present invention, any form can be used as long as it is suitable for obtaining a medicinal effect, and for example, powder, granules, powders, tablets, capsules, syrups, suppositories, injections, ointments. Etc. Of these, external preparations are preferred from the viewpoint of ease of use, and may be in any form as long as they can be applied externally, for example, lotions, liniments, external preparations such as emulsions, creams, ointments, pasta, paps, jellies, sprays and the like. An external semi-solid type agent and the like can be mentioned.
本発明の養毛剤には、有効成分であるシアル酸並びに
シアル酸誘導体全量の配合量は、組成物全量に対して0.
0001〜50重量%、好ましくは0.001〜5重量%である。
0.0001重量%未満では充分な効果が得られにくい傾向に
あり、逆に50重量%を越えても効果の大きな増大を望む
ことは難しい。In the hair nourishing agent of the present invention, the total amount of sialic acid and sialic acid derivative as an active ingredient is 0 based on the total amount of the composition.
It is 0001 to 50% by weight, preferably 0.001 to 5% by weight.
If it is less than 0.0001% by weight, it tends to be difficult to obtain a sufficient effect, and conversely, if it exceeds 50% by weight, it is difficult to expect a large increase in the effect.
本発明の養毛剤は、外用の場合は、皮膚に直接塗布又
は散布する経皮投与による投与方法をとる。又、本発明
の養毛剤の投与量は、年齢、個人差、病状等によって下
記範囲外の量を投与することもあり得るので明確には限
定できないが一般に人を対象とする場合、シアル酸又は
シアル酸誘導体全量の内服及び経皮投与量は、体重1kg
及び1日あたり0.001〜2000mg、好ましくは、0.01〜100
0mgであり、この量を一日に1回又は数回にわけて投与
することができる。In the case of external use, the hair nourishing agent of the present invention is administered by transdermal administration, which is directly applied to or sprayed on the skin. Further, the dose of the hair nourishing agent of the present invention can be administered in an amount outside the following range depending on age, individual difference, medical condition, etc., and thus it is not clearly limited, but when generally intended for humans, sialic acid or sialic acid is used. Oral dose and transdermal dose of all acid derivatives are 1kg
And 0.001 to 2000 mg per day, preferably 0.01 to 100
It is 0 mg, and this amount can be administered once or several times a day.
以下に実施例を示して本発明による養毛剤の製剤化方
法及び養毛効果を具体的に説明する。尚、本発明はこれ
により限定されるものではない。以下、配合量は重量%
である。Hereinafter, the method for formulating the hair nourishing agent and the hair nourishing effect according to the present invention will be specifically described with reference to Examples. The present invention is not limited to this. Below, the blending amount is% by weight
Is.
(養毛剤の製造方法) 95%エタノールにシアル酸Na及び硬化ヒマシ油エチレ
ンオキシド(40モル)付加物を添加し、攪拌溶解させ、
次いでイオン交換水を添加、混合して、実施例1の液状
養毛剤を得た。実施例2〜5並びに比較例1も実施例1
と同様にして得た。使用したシアル酸Na並びにシアル酸
誘導体は、製造例2〜5で製造したものである。(Method for producing hair nourishing agent) Add sodium sialic acid and hydrogenated castor oil ethylene oxide (40 mol) adduct to 95% ethanol, stir and dissolve,
Next, ion-exchanged water was added and mixed to obtain the liquid hair nourishing agent of Example 1. Examples 2 to 5 and Comparative Example 1 are also Example 1
Was obtained in the same manner as. The sodium sialic acid and the sialic acid derivative used were those produced in Production Examples 2-5.
(養毛剤効果試験) 次に本発明の養毛剤の養毛効果を調べるため、 (1)トリコグラム試験、(2)終毛転換率試験を実施
例1〜5及び比較例1の養毛剤について行った。 (Hair nourishing agent effect test) Next, in order to investigate the hair nourishing effect of the hair nourishing agent of the present invention, (1) trichogram test and (2) end hair conversion rate test were conducted on the hair nourishing agents of Examples 1 to 5 and Comparative Example 1.
(1)トリコグラム試験 養毛剤の使用前と使用後の抜去毛髪の毛根を顕微鏡下
で観察し、毛根の形態から休止期毛根数を計数し、その
割合の増減によって養毛剤の養毛効果を比較した。休止
期毛根とは成長の止まった毛の毛根であり、脱毛を訴え
る人は正常な人よりもこの休止期毛根の割合が多いの
で、この休止期毛根の減少から養毛効果を評価した。(1) Trichogram test The hair roots of the removed hair before and after the use of the hair tonic were observed under a microscope, the number of resting hair roots was counted from the form of the hair root, and the hair-restoring effect of the hair tonic was compared by increasing or decreasing the ratio. . Resting hair roots are hair roots of hairs that have stopped growing, and people who complain of hair loss have a higher proportion of resting hair roots than normal people. Therefore, the hair nourishing effect was evaluated from the reduction of resting hair roots.
実施例1〜5及び比較例1の各養毛剤試験液をそれぞ
れ男性被験者10名の頭皮に1日2回、1回2mlずつ6ケ
月間連続して塗布し、塗布直前及び6カ月間塗布終了直
後に被験者1名につき100本ずつ毛髪を除去し、それぞ
れの毛根を調べた。養毛剤使用前に対する使用後の休止
期毛根の割合の変化率を求め、15%以上減少した場合を
有効例とし、有効率を求めた。結果を表−2に示した。Each of the hair nourishment test solutions of Examples 1 to 5 and Comparative Example 1 was applied to the scalp of 10 male subjects twice a day, 2 ml each, continuously for 6 months, immediately before and immediately after the application for 6 months. 100 hairs were removed from each subject and the hair roots were examined. The change rate of the ratio of resting hair roots after the use of the hair nourishing agent was calculated, and the effective rate was calculated when the reduction rate was 15% or more. The results are shown in Table-2.
(2)終毛転換率試験 男性型脱毛症の被験者30名の各々の頭部うぶ毛部位3
か所において、前記の各試験液(実施例1〜5及び比較
例1)の塗布前後における、うぶ毛から終毛への転換率
を比較した。終毛とはうぶ毛以外の毛、すなわち長さ14
mm以上の毛をいい、うぶ毛から終毛への転換は養毛効果
を意味する。1群5名の6群に分け、1群ごとに各試験
液を1日2回(朝、晩)、4カ月間頭部全体に塗布し
た。各試験液の塗布直前及び4カ月塗布直後に、前記の
頭部うぶ毛部位を接写写真撮影して転換率を測定し、終
毛への転換率は3カ所の平均をパーセントで示した。養
毛効果の判定は、平均終毛転換率%10以上を有効とし、
10%未満を無効と判断した。結果を表−3に示す。 (2) End hair conversion rate test 30 heads of each of the 30 male pattern baldness subjects
In each place, the conversion rate from downy hair to terminal hair was compared before and after the application of each test solution (Examples 1 to 5 and Comparative Example 1). End hair is hair other than downy, that is, length 14
It means hair of mm or more, and the conversion from downy hair to terminal hair means a hair nourishing effect. The test solution was divided into 6 groups of 5 people per group, and each test solution was applied to each group twice a day (morning and evening) for 4 months. Immediately before the application of each test solution and immediately after application for 4 months, the conversion of the above-mentioned head fluff portion was taken by taking a close-up photograph, and the conversion rate to the terminal hair was shown as an average of the three positions in percentage. For the determination of the hair nourishing effect, the average terminal hair conversion rate of 10% or more is effective,
Less than 10% was judged invalid. The results are shown in Table-3.
(結果) 表−2、3の試験結果から、シアル酸並びにシアル酸
誘導体に優れた養毛効果があり、又、シアル酸並びにシ
アル酸誘導体を二種以上組合わせると相乗効果が得られ
ることも認められた。尚、両試験において、副作用をう
ったえる被験者はゼロで、且つフケ、カユミが抑まった
と言う被験者が多かったことから、安全性の高い養毛剤
であることが判明した。 (Results) From the test results of Tables 2 and 3, sialic acid and sialic acid derivatives have an excellent hair-growth effect, and when two or more kinds of sialic acid and sialic acid derivatives are combined, a synergistic effect can be obtained. Admitted. In both tests, there were no subjects who complained of side effects, and many subjects reported that dandruff and itchiness were suppressed. Therefore, it was proved to be a highly safe hair nourishing agent.
次に各種実施態様を示す。以下、配合量は重量%とす
る。Next, various embodiments will be shown. In the following, the blending amount will be% by weight.
実施例6 W/0乳化型養毛剤 (重量%) ポリオキシエチレン(60モル) 付加硬化ヒマシ油 2.0 グリセリン 10.0 ジプロピレングリコール 10.0 1,3−ブチレングリコール 5.0 ポリエチレングリコール1500 5.0 セチルイソオクタネート 10.0 スクワラン 5.0 ワセリン 2.0 プロピルパラベン 2.0 カルボキシビニルポリマー1%水溶液 30.0 ヘキサメタリン酸ソーダ 0.03 カセイカリ 0.12 シアル酸Na 1.0 イオン交換水 残余 実施例7 クリーム状養毛剤 (重量%) シアル酸結合オリゴ糖 5.0 シアル酸結合タン白 2.0 シアル結合脂質 0.0001 流動パラフィン 5.0 セトステアリルアルコール 5.5 グリセリルモノステアレート 3.0 EO(20モル)−2−オクチルドデシルエーテル 3.0 プロピルパラベン 0.3 香料 0.1 グリセリン 8.0 ジプロピレングリコール 20.0 ポリエチレングリコール4000 5.0 ヘキサメタリン酸ソーダ 0.005 イオン交換水 残余 実施例8 錠剤 シアル酸Ca50mg、シアル酸結合オリゴ糖50mg、シアル
酸結合脂質50mg、シアル酸結合タン白50mgと微結晶セル
ロース100mgとを含有する錠剤を常法に従って調整し、
シロップゼラチン沈降性炭酸カルシウムで糖衣をほどこ
した。この錠剤は1回の投与量1〜10錠で使用される。Example 6 W / 0 Emulsifying hair nourishing agent (% by weight) Polyoxyethylene (60 mol) Additive hydrogenated castor oil 2.0 Glycerin 10.0 Dipropylene glycol 10.0 1,3-Butylene glycol 5.0 Polyethylene glycol 1500 5.0 Cetyl isooctanate 10.0 Squalane 5.0 Vaseline 2.0 Propyl paraben 2.0 Carboxyvinyl polymer 1% aqueous solution 30.0 Sodium hexametaphosphate 0.03 Causticari 0.12 Na sialic acid 1.0 Ion-exchanged water Residual Example 7 Cream hair nourishing agent (% by weight) Sialic acid-binding oligosaccharide 5.0 Sialic acid-binding protein 2.0 Sial-binding lipid 0.0001 Liquid paraffin 5.0 Cetostearyl alcohol 5.5 Glyceryl monostearate 3.0 EO (20 mol) -2-octyldodecyl ether 3.0 Propylparaben 0.3 Perfume 0.1 Glycerin 8.0 Dipropylene glycol 20.0 Polyethylene glycol 4000 5.0 F Sodium xametaphosphate 0.005 Ion-exchanged water Residual Example 8 Tablets Tablets containing 50 mg of sialic acid Ca, 50 mg of sialic acid-bound oligosaccharide, 50 mg of sialic acid-bound lipid, 50 mg of sialic acid-bound protein and 100 mg of microcrystalline cellulose were prepared according to a conventional method. Then
Syrup gelatin-precipitated calcium carbonate was sugar coated. The tablets are used in a single dose of 1 to 10 tablets.
実施例9 顆粒剤 シアル酸結合オリゴ糖20gと乳糖80g、水10gおよび微
結晶セルロース90gを均一混合し、破砕造粒し、乾燥、
篩別して顆粒剤を得た。この顆粒剤は1回の投与量0.5
〜10gで使用される。Example 9 Granules 20 g of sialic acid-bound oligosaccharide, 80 g of lactose, 10 g of water and 90 g of microcrystalline cellulose were uniformly mixed, crushed and granulated, dried,
Sieve to obtain granules. This granule is 0.5 per dose
Used at ~ 10g.
実施例10 カプセル剤 シアル酸結合タン白100mgと微結晶セルロース100mgお
よび乳糖200mgを均一混合。このカプセル剤は1回の投
与量1〜10カプセルで使用される。Example 10 Capsule 100 mg of sialic acid-bound protein, 100 mg of microcrystalline cellulose and 200 mg of lactose were uniformly mixed. This capsule is used in a single dose of 1 to 10 capsules.
実施例11 軟膏 流動パラフィン(95%)とポリエチレン(5%)より
成るプラスチベース50W 47.5gにシアル酸結合オリゴ糖
2.5gを練合し、減圧脱気して軟膏を得た。この軟膏は1
日4〜5回幹部に塗布される。Example 11 Ointment 47.5 g of plastic base 50W composed of liquid paraffin (95%) and polyethylene (5%) was added to sialic acid-bound oligosaccharide.
2.5 g was kneaded and deaerated under reduced pressure to obtain an ointment. This ointment is 1
It is applied to the executives 4-5 times a day.
本発明の養毛剤は安全性が高く、優れた育毛、脱毛予
防、フケ・カユミ抑制効果をもつ養毛剤である。The hair nourishing agent of the present invention is a highly safe hair nourishing agent having excellent effects on hair growth, hair loss prevention and dandruff / itchiness.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 十河 幸夫 神奈川県横浜市南区井土ケ谷中町157 ダイヤパレス井土ヶ谷703号 (72)発明者 阿彦 健吉 東京都小平市花小金井2―688―18 (72)発明者 出家 栄記 埼玉県狭山市入間川2丁目23番5号102 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Yukio Togawa Yukio Togawa 157 Idogaya Yanaka-cho, Minami-ku, Yokohama-shi Kanagawa 703 Diamond Palace Idogaya 703 (72) Inventor Kenkichi Ahiko 2-688-18 Hanakoganei, Kodaira-shi, Tokyo ( 72) Inventor Eike Eiki 2-23-5 Irumagawa, Sayama City, Saitama Prefecture 102
Claims (4)
ら選択された一種又は二種以上を含有してなる養毛剤。1. A hair nourishing agent containing one or more selected from the group consisting of sialic acid and sialic acid derivatives.
シアル酸結合タン白、シアル酸結合脂質並びにシアル酸
塩である特許請求の範囲第(1)項記載の養毛剤。2. A sialic acid derivative is a sialic acid-linked oligosaccharide,
The hair nourishing agent according to claim (1), which is a sialic acid-binding protein, a sialic acid-binding lipid or a sialic acid salt.
ル酸誘導体を用いる特許請求の範囲第(1)項又は第
(2)項記載の養毛剤。3. The hair nourishing agent according to claim (1) or (2), which uses sialic acid or a sialic acid derivative obtained by extraction from milk.
る特許請求の範囲第(1)項、第(2)項又は第(3)
項記載の養毛剤。4. The sialic acid is N-acetylneuraminic acid. Claims (1), (2) or (3).
The hair restorer according to the item.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP32357087A JP2555389B2 (en) | 1987-12-21 | 1987-12-21 | Hair restorer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP32357087A JP2555389B2 (en) | 1987-12-21 | 1987-12-21 | Hair restorer |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH01163114A JPH01163114A (en) | 1989-06-27 |
JP2555389B2 true JP2555389B2 (en) | 1996-11-20 |
Family
ID=18156176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP32357087A Expired - Lifetime JP2555389B2 (en) | 1987-12-21 | 1987-12-21 | Hair restorer |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2555389B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016079912A1 (en) * | 2014-11-20 | 2016-05-26 | 江崎グリコ株式会社 | Hair papilla cell activator |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2747967B2 (en) * | 1993-07-23 | 1998-05-06 | 雪印乳業株式会社 | Sialic acid powder |
JP2009073806A (en) * | 2007-08-27 | 2009-04-09 | Iriya Cosmetics Co Ltd | Insulin-like growth factor-1 secretagogue |
JPWO2009144977A1 (en) * | 2008-05-28 | 2011-10-06 | 研二 岡嶋 | Oral hair growth composition |
KR101386979B1 (en) * | 2010-10-20 | 2014-04-18 | 주식회사 베네비오 | Compositions for Hair Removal |
CN103655218A (en) * | 2013-11-14 | 2014-03-26 | 无锡西玛生物科技有限公司 | Hair growth shampoo |
CN104146885A (en) * | 2014-07-14 | 2014-11-19 | 武汉中科光谷绿色生物技术有限公司 | Application of N-acetylneuraminic acid hydrate in hair care product |
-
1987
- 1987-12-21 JP JP32357087A patent/JP2555389B2/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016079912A1 (en) * | 2014-11-20 | 2016-05-26 | 江崎グリコ株式会社 | Hair papilla cell activator |
Also Published As
Publication number | Publication date |
---|---|
JPH01163114A (en) | 1989-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4903131B2 (en) | Use of a compound comprising D-mannoheptulose and / or perseitol for the treatment and prevention of innate immune modulatory diseases | |
JP5635226B2 (en) | Hair papilla cell growth promoter | |
BRPI0808065B1 (en) | NEW COSMETIC AND / OR PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATIONS | |
JP2008105983A (en) | Fibroblast proliferation promoter, skin care preparation for external use, bathing agent, and food and drink | |
JP2557240B2 (en) | Skin anti-aging agent | |
JPH03220129A (en) | Sebum suppressant | |
JP2555389B2 (en) | Hair restorer | |
JP2008088075A (en) | Profilaggrin/filaggrin production promoter, epidermal keratinocyte proliferation promoter, skin care preparation for normalizing epidermis/horny cell layer, profilaggrin/filaggrin production-promoting method and epidermal keratinocyte proliferation-promoting method | |
CN108078871B (en) | A kind of mouthwash of the rare saponin(e containing Radix Notoginseng and preparation method thereof | |
JP4430770B2 (en) | Skin elasticity improver | |
JP2684179B2 (en) | Anti-inflammatory agent | |
JPH05262635A (en) | Dermatic external preparation | |
JP2557241B2 (en) | Anti-pigmenting agent | |
JPH10175868A (en) | Water (of chinese medicine idea) improving composition | |
JPH03167113A (en) | Hair regenerating agent | |
JP5155543B2 (en) | Endothelin-1 production inhibitor, hexosaminidase release inhibitor, anti-inflammatory / whitening skin preparation, endothelin-1 production inhibition method, and hexosaminidase release inhibition method | |
JPH0665041A (en) | Skin external preparation | |
KR102204367B1 (en) | Cosmetic compositions for improving skin wrinkle | |
GB2572322A (en) | A hair treatment composition | |
CN110897921B (en) | Acne-removing skin care product containing regenerative medical materials and preparation method thereof | |
CN115869352B (en) | Traditional Chinese medicine compound preparation for treating androgenetic alopecia and preparation method and application thereof | |
US5190916A (en) | Use of ovomacroglobulin as an agent for treating wound and inflammation | |
JPH10147514A (en) | Cosmetic | |
JP5313524B2 (en) | Anti-inflammatory agent and anti-inflammatory skin external preparation | |
JP3135294B2 (en) | External preparation for skin |